A single oral dose of<unk>  in humans that results in symptoms of overdose or that is considered to be life-threatening has not been established. Dosages of up to 600 mg/day have been well tolerated in clinical trials, and it is notable that there is a saturation of absorption with<unk>  such that circulating levels of its active (R)-enantiomer do not further increase above a dosage of 300 mg/day. Overdose is considered unlikely to be life-threatening with<unk>  or other first-generation (i.e., flutamide and nilutamide). A massive overdose of nilutamide (13 grams, or 43 times the normal maximum 300 mg/day clinical dosage) in a 79-year-old man was uneventful, producing no clinical signs, symptoms, or toxicity. There is no specific antidote for<unk>  or overdose, and treatment should be based on symptoms, if any are present.
Bicalutamide
Darolutamide
Topilutamide
Apalutamide
Nilutamide
Acetothiolutamide
Flutamide
Enzalutamide